Mainz Biomed N.V. (NASDAQ:MYNZ) completed a $6 million private placement on February 17, 2026, after entering into the agreement on February 13. The financing is structured in two tranches of $3 million each; the first tranche closed on February 13, and the second tranche is expected to close before April 15, subject to stockholder approval.
The capital raised will be used to strengthen the company’s liquidity position and accelerate the development of its PancAlert pancreatic cancer screening program. PancAlert is a non‑invasive, blood‑based test that has received public funding from the Investitions‑ und Strukturbank Rheinland‑Pfalz, covering up to 50% of project costs. The funding will also support a strategic shift toward U.S. operations and the divestiture of legacy colorectal cancer assets, including the winding down of the German subsidiary.
Management highlighted that the private placement will allow Mainz Biomed to focus resources on PancAlert, which has shown promising early‑stage results. David Lazar, a significant investor in the placement, has been appointed Chairman of the Board, signaling a new governance direction. "Our immediate focus is to continue to further develop and evaluate opportunities to grow our pancreatic screening program in the U.S. and stabilize the business," Lazar said.
Financially, the company has faced persistent losses and negative operating cash flow. In the first half of 2025, revenue fell 45% from the first half of 2024, driven by the cessation of direct‑to‑consumer sales and the sale of its European Oncology Lab business. However, gross margin improved from 61% to 66% due to cost efficiencies and increased sales to laboratory partners. The private placement provides the liquidity needed to sustain operations while the company pursues its high‑growth PancAlert pipeline.
The event represents a significant capital structure change and a strategic pivot that could reshape Mainz Biomed’s future revenue mix and competitive positioning. The infusion of capital and the appointment of a new chairman are expected to enhance the company’s ability to execute its development plans and potentially unlock value for stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.